[1] 李超, 韦洮. 尿毒症毒素新分类解读[J]. 中国血液净化. 2023, 22(11):801–804, 815.
[2] Sánchez OD, Mas FS, Gracia IC, et al. Displacing the Burden: A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease[J]. JCM. 2024, 13(5):1428.
[3] Vanholder R, De SR, Glorieux G,et al. Review on uremic toxins: Classification, concentration, and interindividual variability[J]. Kidney Int. 2003, 63(5):1934–1943.
[4] Duranton F, Cohen G, De SR, et al. Normal and Pathologic Concentrations of Uremic Toxins[J]. J Am Soc Nephrol. 2012, 23(7):1258–1270.
[5] Rosner MH, Reis T, Husain SF, et al. Classification of Uremic Toxins and Their Role in Kidney Failure [J]. Clin J Am Soc Nephrol. 2021, 16(12):1918–1928.
[6] Vanholder R, De SR, Lameire N. Protein-bound uremic solutes: The forgotten toxins [J]. Kidney Int. 2001, 59(78):S266–270.
[7] Vanholder R, Van LN, De SR. Drug protein binding in chronic renal failure: Evaluation of nine drugs [J]. Kidney Int. 1988, 33(5):996–1004.
[8] Vanholder R, Pletinck A, Schepers E, et al. Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update [J]. Toxins (Basel). 2018, 10(1):33.
[9] Florens N, Yi D, Juillard L, et al. Using binding competitors of albumin to promote the removal of protein-bound uremic toxins in hemodialysis: Hope or pipe dream[J]. Biochimie. 2018, 144:1–8.
[10] Sirich TL, Meyer TW, Gondouin B, et al. Protein-Bound Molecules: A Large Family With a Bad Character [J]. Semin Nephrol. 2014, 34(2):106–117.
[11] Saar KV, Zidek W, Orth AS, et al. Reduction of protein‐bound uraemic toxins in plasma of chronic renal failure patients: A systematic review [J]. J Intern Med. 2021, 290(3):499–526.
[12] Aronov PA, Luo FJG, Plummer NS, et al. Colonic contribution to uremic solutes [J]. J Am Soc Nephrol. 2011, 22(9):1769–1776.
[13] Atherton JG, Hains DS, Bissler J, et al. Generation, clearance, toxicity, and monitoring possibilities of unaccounted uremic toxins for improved dialysis prescriptions [J]. Am J Physiol Renal Physiol. 2018, 315(4):F890–902.
[14] Faria M, dePinho MN. Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease [J]. Transl Res. 2021, 229:115–134.
[15] Viaene L, Annaert P, De LH, et al. Albumin is the main plasma binding protein for indoxyl sulfate and p‐cresyl sulfate [J]. Biopharm Drug Dispos. 2013, 34(3):165–175.
[16] Dehghan NV, Unsworth LD. Detailing Protein-Bound Uremic Toxin Interaction Mechanisms with Human Serum Albumin in the Pursuit of Designing Competitive Binders [J]. Int J Mol Sci. 2023, 24(8):7452.
[17] Zare F, Janeca A, Jokar SM, et al. Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal [J]. Membranes (Basel). 2022, 12(3):261.
[18] Deltombe O, De Loor H, Glorieux G, et al. Exploring binding characteristics and the related competition of different protein-bound uremic toxins [J]. Biochimie. 2017, 139:20–26.
[19] Deltombe O, Van Biesen W, Glorieux G, et al. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis [J]. Toxins (Basel). 2015, 7(10):3933–3946.
[20] Meijers B, Toussaint ND, Meyer T, et al. Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis [J]. Am J Nephrol. 2011, 34(3):226–232.
[21] 任真真, 伦立德. 蛋白结合类尿毒症毒素蛋白结合率方法测定[J]. 空军医学杂志. 2015, 31(5):284–287.
[22] Holmar J, de la PSS, Floege J, et al. Uremic Toxins Affecting Cardiovascular Calcification: A Systematic Review [J]. Cells. 2020, 9(11):2428.
[23] Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells [J]. Kidney Int. 2006, 69(10):1780–1785.
[24] Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair [J]. Kidney Int. 2004, 65(2):442–451.
[25] Dou L, Jourde CN, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells [J]. J Thromb Haemost. 2007, 5(6):1302–1308.
[26] Pletinck A, Glorieux G, Schepers E, et al. Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall [J]. J Am Soc Nephrol. 2013, 24(12):1981–1994.
[27] 黄佳, 雷涓涓, 李寒, 等. 维持性血液透析患者高同型半胱氨酸血症和心脏结构的相关性分析[J], 中国血液净化, 2023, 22(6):401–405.
[28] 孙静, 赵燚, 孙仙. 同型半胱氨酸水平与代谢性心血管疾病相关性的meta分析[J]. 临床心血管病杂志. 2024, 40(2):108–115.
[29] Jankowski J, Vander GM, Jankowski V, et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression [J]. J Clin Invest. 2003, 112(2):256–264.
[30] Adijiang A, Higuchi Y, Nishijima F, et al. Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats [J]. Biochem Biophys Res Commun. 2010, 399(4):637–641.
[31] Muteliefu G, Enomoto A, Jiang P, et al. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells [J]. Nephrol Dial Transplant. 2009, 24(7):2051–2058.
[32] Lin CJ, Wu V, Wu PC, et al. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure [J]. PLoS One. 2015, 10(7):e0132589.
[33] Lin C, Pan C, Chuang C, et al. Gastrointestinal-related Uremic Toxins in Peritoneal Dialysis: A Pilot Study with a 5-year Follow-up [J]. Arch Med Res. 2013, 44(7):535–541.
[34] Dou L, Sallée M, Cerini C, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid [J]. J Am Soc Nephrol. 2015, 26(4):876–887.
[35] Liu C, Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency [J]. Exp Ther Med. 2018, 17(1):368–372
[36] Kalantar ZK, Kopple JD, Humphreys MH, et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients [J]. Nephrol Dial Transplant. 2004, 19(6):1507–1519.
[37] Gouroju S, Rao PVLNS, Bitla AR, et al. Role of Gut-derived Uremic Toxins on Oxidative Stress and Inflammation in Patients with Chronic Kidney Disease [J]. Indian J Nephrol. 2017, 27(5):359–364.
[38] Anderson MM, Hazen SL, Hsu FF, et al. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation [J]. J Clin Invest. 1997, 99(3):424–432.
[39] Dou L, Poitevin S, Sallée M, et al. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease [J]. Kidney Int. 2018, 93(4):986–999.
[40] Adelibieke Y, Shimizu H, Muteliefu G, et al. Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity [J]. J Ren Nutr. 2012, 22(1):86–89.
[41] 赵景宏. 蛋白结合毒素与慢性肾脏病及其心血管并发症[J]. 临床肾脏病杂志. 2017, 17(5):260–264.
[42] Itoh Y, Ezawa A, Kikuchi K, et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production [J]. Anal Bioanal Chem. 2012, 403(7):1841–1850.
[43] Yamamoto S, Fuller DS, Komaba H, et al. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study [J]. Clin Kidney J. 2021, 14(4):1236–1243.
[44] Wu IW, Hsu KH, Hsu HJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients--a prospective cohort study [J]. Nephrol Dial Transplant. 2012, 27(3):1169–1175.
[45] Lin CJ, Pan CF, Chuang CK, et al. P-Cresyl Sulfate Is a Valuable Predictor of Clinical Outcomes in Pre-ESRD Patients [J]. Biomed Res Int. 2014, 2014:526932.
[46] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识（2018修订版）[J]. 中华肾脏病杂志. 2018, 34(11):860–866.
[47] Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure [J]. Kidney Int Suppl. 2001, 78:S67-72.
[48] Kushner D, Beckman B, Nguyen L, et al. Polyamines in the anemia of end-stage renal disease [J]. Kidney Int. 1991, 39(4):725–732.
[49] Galli F, Beninati S, Benedetti S, et al. Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythropoiesis [J]. Kidney Int Suppl. 2001, 78:S73-76.
[50] Duangchan T, Rattanasompattikul M, Chitchongyingcharoen N, et al. Indoxyl sulfate impairs in vitro erythropoiesis by triggering apoptosis and senescence [J]. Exp Biol Med (Maywood). 2022, 247(15):1350–1363.
[51] Asai H, Hirata J, Watanabe AM. Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factor?dependent erythropoietin expression through activation of aryl hydrocarbon receptor [J]. Biochem Biophys Res Commun. 2018, 504(2):538–544.
[52] Verbeke F, Vanholder R, Van Biesen W, et al. Contribution of Hypoalbuminemia and Anemia to the Prognostic Value of Plasma p-Cresyl Sulfate and p-Cresyl Glucuronide for Cardiovascular Outcome in Chronic Kidney Disease [J]. J Pers Med. 2022, 12(8):1239.
[53] Bataille S, Pelletier M, Sallée M, et al. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients [J]. BMC Nephrol. 2017, 18(1):251.
[54] Takkavatakarn K, Wuttiputinun T, Phannajit J, et al. Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis [J]. J Nephrol. 2021, 34(6):1805–1817.
[55] Marzocco S, Dal PF, Di ML, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease [J]. Blood Purif. 2013, 35(1–3):196–201.
[56] Di Iorio BR, Rocchetti MT, De Angelis M, et al. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study) [J]. J Clin Med. 2019, 8(9):1424.
[57] Black AP, Anjos JS, Cardozo L, et al. Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients [J]. J Ren Nutr. 2018, 28(3):208–214.
[58] Ebersolt M, Santana MT, Mallmann C, et al. Protein/Fiber Index Modulates Uremic Toxin Concentrations in Hemodialysis Patients [J]. Toxins (Basel). 2022, 14(9):589.
[59] Heri? T, Vivoda T, Bogataj ?, et al. Medium Cut-Off Dialysis Membrane and Dietary Fiber Effects on Inflammation and Protein-Bound Uremic Toxins: A Systematic Review and Protocol for an Interventional Study [J]. Toxins (Basel). 2021, 13(4):244.
[60] 中国医师协会肾脏内科医师分会, 中国中西医结合学会肾脏疾病专业委员会营养治疗指南专家协作组. 中国慢性肾脏病营养治疗临床实践指南（2021版）[J]. 中华医学杂志. 2021, 101(8):539–559.
[61] Van GMK, Middel IR, Vernooij RWM, et al. Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome [J]. Toxins (Basel). 2020, 12(4):234.
[62] Snauwaert E, Holvoet E, Van BW, et al. Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population [J]. Toxins (Basel). 2019, 11(4):235.
[63] Zhang M, Wang M, Li H, et al. Association of Initial Twice-Weekly Hemodialysis Treatment with Preservation of Residual Kidney Function in ESRD Patients [J]. Am J Nephrol. 2014, 40(2):140–150.
[64] Chen W, Wang M, Zhang M, et al. Benefits of Incremental Hemodialysis Seen in a Historical Cohort Study [J]. Ther Clin Risk Manag. 2021, 17:1177–1186.
[65] 陈旭娇, 陈思秀, 毛志国. 益生菌降低终末期肾脏疾病蛋白结合毒素的研究进展[J]. 临床肾脏病杂志. 2015, 15(12):758–761.
[66] Thongprayoon C, Kaewput W, Hatch ST, et al. Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2019, 64(2):469–479.
[67] Kikuchi M, Ueno M, Itoh Y, et al. Uremic Toxin-Producing Gut Microbiota in Rats with Chronic Kidney Disease [J]. Nephron. 2017, 135(1):51–60.
[68] Miyazaki T, Aoyama I, Ise M, et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys [J]. Nephrol Dial Transplant. 2000, 15(11):1773–1781.
[69] Lee CT, Hsu CY, Tain YL, et al. Effects of AST-120 on Blood Concentrations of Protein-Bound Uremic Toxins and Biomarkers of Cardiovascular Risk in Chronic Dialysis Patients [J]. Blood Purif. 2014;37(1):76–83.
[70] Akizawa T, Asano Y, Morita S, et al. Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial [J]. Am J Kidney Dis. 2009, 54(3):459–467.
[71] Schulman G, Berl T, Beck GJ, et al. AST120_Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD [J]. J Am Soc Nephrol. 2015, 26(7):1732–1746.
[72] Chen YC, Wu MY, Hu PJ, et al. Effects and Safety of an Oral Adsorbent on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis [J]. J Clin Med. 2019, 8(10):1718.
[73] 张宏, 伦立德. 低通量血液透析对蛋白结合类毒素清除效果的研究[J]. 空军医学杂志. 2016, 32(2):106–109.
[74] 上海市医学会肾脏病专科分会. 血液灌流在维持性血液透析患者中的临床应用上海专家共识[J]. 上海医学. 2021, 44(9):621–627.
[75] Yamamoto S, Sato M, Sato Y, et al. Adsorption of Protein‐Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl‐Immobilized Cellulose Beads in Patients Undergoing Hemodialysis [J]. Artif Organs. 2018, 42(1):88–93.
[76] 欧志强, 伦立德, 李新伦, 等.血液透析联合血液灌流治疗对清除维持性血液透析患者体内蛋白结合类毒素的长期临床研究[J]. 军事医学. 2017, 41(7): 611-614
[77] 张豫, 刘园园, 梅长林, 等. 国产新型血液灌流器清除蛋白结合类毒素的临床疗效研究[J]. 临床肾脏病杂志. 2017, 17(6):345–348.
[78] Zhang Y, Mei CL, Rong S, et al. Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis [J]. Blood Purif. 2015, 40(2):127–132.
[79] 邓岱, 李新伦, 李红霞, 等. 不同血液净化方法清除维持性血液透析患者血清蛋白结合类尿毒症毒素的效果比较[J]. 中国血液净化. 2014, 13(9):639–642.
[80] 张宏, 李新伦, 伦立德. 不同血液净化模式对维持性血液透析患者蛋白结合类毒素的清除效果[J]. 肾脏病与透析肾移植杂志. 2016, 25(5):425–430.
[81] Pedrini LA, De CV, Comelli M, et al. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study[J]. Nephrol Dial Transplant. 2011, 26(8):2617–2624.
[82] Lima JD, Guedes M, Rodrigues SD, et al. High-volume hemodiafiltration decreases the pre-dialysis concentrations of indoxyl sulfate and p-cresyl sulfate compared to hemodialysis: a post-hoc analysis from the HDFit randomized controlled trial[J]. J Nephrol. 2022, 35(5):1449–1456.
[83] Kim YG, Lee SH, Jung SW, et al. The Medium Cut-Off Membrane Does Not Lower Protein-Bound Uremic Toxins[J]. Toxins (Basel). 2022, 14(11):779.
[84] Duval SA, Burtey S, Pelletier M, et al. Systematic Comparison of Uremic Toxin Removal Using Different Hemodialysis Modes: A Single-Center Crossover Prospective Observational Study [J]. Biomedicines. 2023, 11(2):373.
[85] Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial[J]. Nephrol Dial Transplant. 2008, 24(2):562–570.
[86] Thammathiwat T, Tiranathanagul K, Limjariyakul M, et al. Super High-Flux Hemodialysis Provides Comparable Effectiveness with High-Volume Post-dilution Online Hemodiafiltration in Removing Protein-bound and Middle-molecule Uremic Toxins: A Prospective Cross-over Randomized Controlled Trial[J]. Ther Apher Dial. 2021, 25(1):73–81.
[87] 周蕾, 龚德华. 蛋白结合毒素与心血管疾病[J]. 肾脏病与透析肾移植杂志. 2018, 27(3):279–283.
[88] Vanholder RC, Eloot S, Glorieux GLRL. Future Avenues to Decrease Uremic Toxin Concentration[J]. Am J Kidney Dis. 2016, 67(4):664–676.
[89] Sirich TL, Luo FJG, Plummer NS, et al. Selectively increasing the clearance of protein-bound uremic solutes[J]. Nephrol Dial Transplant. 2012, 27(4):1574–1579.
[90] Yu J, Chitalia VC, Akintewe OO, et al. Determinants of Hemodialysis Performance:Modeling Fluid and Solute Transport in Hollow-Fiber Dialyzers[J]. Regen Eng Transl Med. 2021, 7(3):291–300.
[91] Eloot S, Schneditz D, Cornelis T, et al. Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis[J]. PLoS One. 2016, 11(1):e0147159.
[92] Fagugli RM, De Smet R, Buoncristiani U, et al. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis[J]. Am J Kidney Dis. 2002, 40(2):339–347.
[93] Palmer SC, Rabindranath KS, Craig JC, et al. High-flux versus low-flux membranes for end-stage kidney disease[J]. Cochrane Database Syst Rev. 2012(9):CD005016
[94] Eknoyan G, Greene T, Depner TA, et al. Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis[J]. N Engl J Med. 2002, 341(15): 1491-1494.
[95] Locatelli F, Martin Malo A, Hannedouche T, et al. Effect of Membrane Permeability on Survival of Hemodialysis Patients[J]. J Am Soc Nephrol. 2009, 20(3):645–654.
[96] Abe M, Masakane I, Wada A, et al. Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study[J]. Clin Kidney J. 2022, 15(3):473–483.
[97] Tange Y, Takesawa S, Yoshitake S. Asymmetric triacetate membrane keeps high water flux during ultrafiltration: in vitro study[J]. J Artif Organs. 2017, 20(4):399–402.
[98] Chow CM, Persad AH, Karnik R. Effect of Membrane Permeance and System Parameters on the Removal of Protein-Bound Uremic Toxins in Hemodialysis[J]. Ann Biomed Eng. 2024, 52(3):526–541.
[99] Urbani A, Sirolli V. Proteomic investigations on the effect of different membrane materials on blood protein adsorption during haemodialysis[J]. Blood Transfusion. 2012, 10(Suppl 2):S101–112
[100] K?rtge A, Wild T, Heskamp B, et al. Thrombogenicity and long-term cytokine removal capability of a novel asymmetric triacetate membrane hemofilter[J]. J Artif Organs. 2018, 21(4):435–442.
[101] Bonomini M, Piscitani L, Di LL, et al. Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy[J]. Biomedicines. 2022, 10(4):844.
[102] Shen Y, Shen Y, Bi X, et al. Application of Nanoparticles as Novel Adsorbents in Blood Purification Strategies[J]. Blood Purif. 2024, 53(9):743–754.
[103] Tijink MSL, Wester M, Glorieux G, et al. Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma[J]. Biomaterials. 2013, 34(32):7819–7828.
[104] B?hringer F, Jankowski V, Gajjala PR, et al. Release of Uremic Retention Solutes from Protein Binding by Hypertonic Predilution Hemodiafiltration[J]. ASAIO J. 2015, 61(1):55–60.
[105] Clark WR, Dehghani NL, Narsimhan V, et al. Uremic Toxins and their Relation to Dialysis Efficacy[J]. Blood Purif. 2019, 48(4):299–314.
[106] Miyamoto Y, Watanabe H, Noguchi T, et al. Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney[J]. Nephrol Dial Transplant. 2011, 26(8):2498–2502.
[107] Deguchi T, Kusuhara H, Takadate A, et al. Characterization of uremic toxin transport by organic anion transporters in the kidney[J]. Kidney Int. 2004, 65(1):162–174.
[108] Mutsaers HAM, Van Heuvel LP, Ringens LHJ, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations[J]. PLoS One. 2011, 6(4):e18438.
[109] Kawanishi H, Takemoto Y. Scientific Aspects of Dialysis Therapy: JSDT/ISBP Anniversary Edition[M]. Contrib Nephrol. Basel, Karger, 2017, 189:204–209.
[110] Donati G, Cappuccilli M, Donadei C, et al. Toxin Removal and Inflammatory State Modulation during Online Hemodiafiltration Using Two Different Dialyzers (TRIAD2 Study) [J]. Methods Protoc. 2021, 4(2):26.
